Peptides for Weight-Loss Research: A Canadian Guide
Metabolic and weight research is one of the most active areas in modern peptide science, and Canadian laboratories now work with a broad panel of compounds studied across this space. This guide gives an overview of the main classes examined in metabolic and body-composition research: the incretin receptor agonists, an amylin analog, a mitochondrial-derived peptide, and a small-molecule enzyme inhibitor. Each acts through a distinct molecular pathway, and understanding those differences is the foundation of sound in vitro and preclinical study design.
The largest group is the incretin agonists. These molecules mimic gut hormones that are released after nutrient intake and that signal to the pancreas, brain, and gastrointestinal tract to influence glucose handling and satiety pathways. The compounds below span single, dual, and triple receptor activity, which is the primary axis along which researchers compare them.
| Compound | Class | Primary target | Research focus |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | GLP-1 receptor | Glucose regulation and satiety signaling |
| Tirzepatide | Dual GIP and GLP-1 agonist | GIP and GLP-1 receptors | Combined incretin effect on metabolism |
| Retatrutide | Triple GIP, GLP-1 and glucagon agonist | GIP, GLP-1 and glucagon receptors | Energy expenditure and body composition |
| Cagrilintide | Long-acting amylin analog | Amylin and calcitonin receptors | Satiety and gastric emptying |
| MOTS-c | Mitochondrial-derived peptide | AMPK signaling pathway | Insulin sensitivity and metabolic homeostasis |
| 5-Amino-1MQ | Small-molecule NNMT inhibitor | Nicotinamide N-methyltransferase | Adipocyte metabolism and NAD balance |
The incretin agonists
Semaglutide is a GLP-1 receptor agonist built on the native glucagon-like peptide-1 backbone, modified with a fatty-acid side chain that promotes albumin binding and extends its circulating half-life to roughly one week. Preclinical and clinical research has examined its influence on glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite signaling in the hypothalamus. A side-by-side look at the single agonist and the triple agonist is available in this semaglutide and retatrutide comparison.
Tirzepatide adds a second mechanism. It is a dual agonist that activates both the GIP and GLP-1 receptors, and studies suggest the combined incretin signal produces metabolic effects distinct from GLP-1 activity alone. Its research profile has centered on glucose control and body-weight endpoints in preclinical models. The tirzepatide and retatrutide comparison walks through how dual and triple agonism differ.
Retatrutide extends the concept further as a triple agonist targeting the GIP, GLP-1, and glucagon receptors. The added glucagon-receptor component is of particular interest in energy-expenditure research, since glucagon signaling can influence hepatic metabolism and thermogenesis. It is the most recently developed of the incretin compounds studied here and remains a frequent subject of body-composition investigation.
The amylin analog
Cagrilintide works outside the incretin family. It is a long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells, and it engages the amylin and calcitonin receptor systems. Research has examined its role in satiety and gastric emptying, and it is often studied alongside GLP-1 agonists because the two mechanisms are complementary. The cagrilintide and semaglutide comparison covers how the amylin and GLP-1 pathways contrast.
Mitochondrial and enzymatic targets
MOTS-c represents a different concept entirely. It is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S ribosomal RNA region of mitochondrial DNA. Research has linked it to activation of the AMPK pathway, a central regulator of cellular energy balance, and preclinical work has investigated its effects on insulin sensitivity and metabolic homeostasis under stress conditions.
5-Amino-1MQ is not a peptide at all but a small-molecule inhibitor of nicotinamide N-methyltransferase, or NNMT, an enzyme highly expressed in adipose tissue. By inhibiting NNMT, research has explored how the compound may shift adipocyte metabolism and preserve cellular NAD pools, which makes it a point of interest in metabolic and body-composition studies.
Handling and measurement
Most of these compounds arrive as a lyophilized powder that is reconstituted with bacteriostatic water for laboratory use. Reconstitution is a measurement exercise, not a dosing one: adding 2 mL of diluent to a 10 mg vial produces a concentration of 5 mg per mL, which is 5000 mcg per mL. Working out these mg to mcg conversions accurately is essential for consistent in vitro measurements, and the interactive reconstitution calculator handles the arithmetic. Lyophilized vials are generally stored frozen, while reconstituted material is kept refrigerated and protected from light.
For a wider survey of this field, the overview of research peptides studied in metabolic and weight research places these compounds in context. To see current Canadian stock, purity documentation, and vial sizes, browse the store.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.